Agilent & Veeda Lifesciences Strengthen Biopharma Analytics with New Facility
The partnership aims to address growing complexities in biologics development, particularly in areas such as GLP-1 drugs and other large-molecule therapies.
Agilent Technologies, a global leader in analytical instrumentation headquartered in the United States, has partnered with Veeda Lifesciences, an India-based contract research organization (CRO), to combine their expertise in advanced analytical technologies and clinical research services.
Agilent Technologies and Veeda Lifesciences have jointly established a new analytical Centre of Excellence (CoE) aimed at strengthening regulatory-ready biopharma analytics.
The facility is designed to support the development of complex biologics, including GLP-1 therapies, which are increasingly in demand for treating conditions such as diabetes and obesity.
Agilent Technologies, a global leader in analytical instrumentation headquartered in the United States, has partnered with Veeda Lifesciences, an India-based contract research organization (CRO), to combine their expertise in advanced analytical technologies and clinical research services.
The collaboration is focused on enhancing capabilities in method development, validation, and regulatory compliance.
“As GLP-1 and other complex therapies move rapidly through development, the need for robust, regulatory-aligned analytics becomes increasingly critical,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Through our collaboration with Veeda, we aim to support biopharma organizations with workflow-driven analytical approaches that strengthen data quality, compliance, and confidence across the development lifecycle.”
The newly launched CoE will provide integrated analytical services to biopharma companies, helping accelerate drug development timelines while ensuring adherence to global regulatory standards. It will leverage Agilent’s instrumentation and software solutions alongside Veeda’s experience in bioanalytical and clinical research.
The partnership aims to address growing complexities in biologics development, particularly in areas such as GLP-1 drugs and other large-molecule therapies. By offering end-to-end analytical support, the companies intend to help pharmaceutical firms navigate stringent regulatory requirements more efficiently.
“As Biopharma innovation accelerates across the region, the need for integrated, regulatory ready analytical ecosystems is becoming increasingly critical,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “This collaboration between Agilent and Veeda Lifesciences reflects our commitment to enabling customers with advanced, scalable solutions that support confident decision-making across the drug development lifecycle, while Asia Pacific’s role as a hub for high quality- globally relevant biopharma research.”
Through this initiative, both companies are looking to strengthen their presence in the global biopharma services market while supporting innovation in next-generation therapeutics.
Stay tuned for more such updates on Digital Health News
Follow us
